Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Spruce Biosciences (SPRB) Invested Capital (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Invested Capital for 4 consecutive years, with $42.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 39.66% to $42.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.5 million, a 39.66% increase, with the full-year FY2025 number at $42.5 million, up 39.66% from a year prior.
  • Invested Capital was $42.5 million for Q4 2025 at Spruce Biosciences, up from $5.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $109.6 million in Q1 2023 to a low of $5.9 million in Q3 2025.
  • A 4-year average of $62.8 million and a median of $69.2 million in 2022 define the central range for Invested Capital.
  • Biggest YoY gain for Invested Capital was 39.66% in 2025; the steepest drop was 88.88% in 2025.
  • Spruce Biosciences' Invested Capital stood at $70.1 million in 2022, then increased by 11.44% to $78.1 million in 2023, then plummeted by 61.04% to $30.4 million in 2024, then surged by 39.66% to $42.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Invested Capital are $42.5 million (Q4 2025), $5.9 million (Q3 2025), and $14.1 million (Q2 2025).